2024
Lupus erythematosus and dermatomyositis
Ramachandran S, Little A, Gehlhausen J. Lupus erythematosus and dermatomyositis. Clinics In Dermatology 2024, 43: 147-152. PMID: 39694200, DOI: 10.1016/j.clindermatol.2024.12.009.Peer-Reviewed Original ResearchLupus erythematosusSystemic diseaseTraining of dermatologistsManifestation of systemic diseaseSymptoms of systemic lupus erythematosusCutaneous manifestations of systemic diseaseAutoimmune connective tissue diseaseSystemic lupus erythematosusConnective tissue diseaseSigns of systemic diseasePatient carePhysical examination findingsInternal medicineCutaneous manifestationsYoung dermatologistsTissue diseaseClinicopathologic correlationPathological findingsExamination findingsSkin signsSystem pathologyField of dermatologyClinical signsObservation skillsMixed and undifferentiated autoimmune connective tissue diseases
Vesely M. Mixed and undifferentiated autoimmune connective tissue diseases. Clinics In Dermatology 2024, 43: 160-165. PMID: 39681290, DOI: 10.1016/j.clindermatol.2024.12.011.Peer-Reviewed Original ResearchConnective tissue diseaseTissue diseaseCutaneous manifestationsUndifferentiated connective tissue diseaseAutoimmune connective tissue diseaseEra of molecular diagnosticsSigns of systemic diseaseUrticarial vasculitisSystemic complicationsSjogren's syndromeClinical entityDescription of patientsSystemic diseaseClinical observationsDisease characterizationMolecular diagnosticsDiseasePatientsVasculitis
2020
Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope
Hinchcliff M, O’Reilly S. Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope. Current Rheumatology Reports 2020, 22: 42. PMID: 32562016, PMCID: PMC7305248, DOI: 10.1007/s11926-020-00918-3.Peer-Reviewed Original ResearchConceptsSkin fibrosisNew targetsSSc interstitial lung diseaseAutoimmune connective tissue diseaseSystemic sclerosis therapyConnective tissue diseaseInterstitial lung diseaseCurrent ongoing trialsNew therapeutic targetsActivation of fibroblastsPotential new targetsReviewSystemic sclerosisSclerosis therapyOngoing trialsTissue diseaseLung diseaseClinical trialsTherapeutic targetRate of declineDisease pathogenesisPhase IIIPhase IIFibrosisNew hopeDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply